Enrolling Now: Phase 2 trial to evaluate the safety and efficacy of SPR001 in adults with classic CAH

If you are an adult with a genetic diagnosis of classic Congenital Adrenal Hyperplasia, you may be eligible to participate in a Phase 2 clinical trial for a new, once-a-day therapy for CAH.

The Phase 2 clinical trial will test the safety and efficacy of a one-a-day pill for Congenital Adrenal Hyperplasia. To learn more, and see if you may qualify, go to www.CAHclinicaltrial.com

Patient Resources

Learn more about Congenital Adrenal Hyperplasia

If you or a loved one has been diagnosed with congenital adrenal hyperplasia (CAH) or other adrenal disorders, it’s best to stay informed. Learn more about CAH so you can make informed decisions on a treatment plan.

Learn more

Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. Our mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal (HPA) axis (the “stress pathway”). We are committed to transforming the quality of life for patients who have been underserved by scientific innovation.